| atezolizumab based treatment | avelumab based treatment | durvalumab based treatment | pembrolizumab alone |
| atezolizumab alone | avelumab alone | durvalumab alone | pembrolizumab (10mg/kg) | pembrolizumab (2mg/kg) |
| mNSCLC - L2 - PDL1 positive 7 | | | | | |
Comparator:
vs docetaxel; vs Standard of Care (SoC);
Risk of bias:
low;
some concerns;
high;
NA;